Adiponutrin is a newly described white adipose tissue (WAT)-derived protein whose function and regulation remain widely unclear in humans though it is suggested to be related to insulin sensitivity. Recently, we found that adiponutrin expression is reduced in type 2 diabetic subjects in basal and insulinstimulated states. To examine adiponutrin regulation by the insulin pathway in relation to other WAT-related proteins with well-known relation to insulin signaling and action, we examined in healthy young men (1) the association of adiponutrin with p85a PI3K and HKII, leptin, adiponectin, and acylation-stimulating protein (ASP) and (2) the regulation of adiponutrin and WAT-derived proteins by 3-h hyperinsulinemic euglycemic clamp (HIEG). At baseline (NZ20), adiponutrin expressions were positively correlated with those of p85a PI3K (RZ0 . 54 levels. In healthy young men, adiponutrin expression is unregulated by hyperinsulinemia and is related to basal and/or insulin-stimulated p85a PI3K, HKII, adiponectin, and leptin expression levels. We hypothesize that insulin-mediated regulation of adiponutrin expression is under the PI3K pathway. The relevance of the present findings to reduced adiponutrin expression in type 2 diabetes is discussed.
Introduction
Adiponutrin is a newly described non-secreted protein mainly expressed in brown and white adipose tissues (WAT; Baulande et al. 2001 , Kershaw et al. 2006 . To date, the physiological function of adiponutrin is unknown though it is suggested that adiponutrin may facilitate lipid storage in WAT (Jenkins et al. 2004 , Lake et al. 2005 , Kershaw et al. 2006 . Similarly, the physiological regulation of adiponutrin expression is still being explored but several lines of evidence, mainly in rodents, suggest that adiponutrin may be regulated by energy balances and particularly by insulin.
In vitro, adiponutrin expression increases with differentiation of murine pre-adipocytes and is induced by glucose and insulin treatments of these cells (Baulande et al. 2001 , Kershaw et al. 2006 . Accordingly, adiponutrin expression in rodent's WAT decreases with fasting (Baulande et al. 2001 , Bertile & Raclot 2004 , Wiesner et al. 2004 , Kershaw et al. 2006 ) and increases with refeeding (Baulande et al. 2001 , Kershaw et al. 2006 and with the ingestion of highcarbohydrate and high-protein meals (Polson & Thompson 2003 . Moreover, WAT adiponutrin expression is decreased in two mice models of altered insulin action: the insulin-receptor knockout mice and the insulin-deficient mice (streptozotocin-induced diabetes), a defect that is corrected upon insulin replacement in this later mouse model (Kershaw et al. 2006) . Finally, as adiponutrin expression is increased in obese fa/fa Zucker rats (having increased ob gene expression) (Guerre-Millo 1997 , Baulande et al. 2001 , while it is reduced in leptin-deficient obese ob/ob mice (Lake et al. 2005) , leptin pathway may be implicated in the regulation of adiponutrin expression.
Little is known about adiponutrin regulation in human. To date only two studies were reported, results of which are partially inconsistent with each other and murine data. S.c. WAT adiponutrin expression was not increased in obese subjects and was associated with insulin sensitivity in one study (Liu et al. 2004) but not in the other (where insulin sensitivity was associated with adiponutrin expression in visceral WAT only; Johansson et al. 2006 ). However, both human studies suggest that adiponutrin expression may be regulated by insulin and glucose. In one study, adiponutrin expression in WAT was decreased after energy restriction and was increased upon refeeding (Liu et al. 2004) and in the other, adiponutrin expression in cultured human adipocytes was induced by insulin in a glucose-dependent manner (Johansson et al. 2006) .
Clearly much remains to be explored regarding the regulation of adiponutrin in human, particularly given the possible role of adiponutrin in insulin sensitivity. Recently, we examined the regulation of adiponutrin expression by hyperinsulinemia in type 2 diabetic obese subjects. Despite their obese state and the origin of adiponutrin being WAT, fasting adiponutrin expression as well as insulinstimulated increase in adiponutrin expression were reduced in obese diabetic subjects when compared with controls (Moldes et al. 2006) .
Insulin sensitivity as well as the regulation of many WATderived proteins involved in insulin action are defective in type 2 diabetes and may affect the regulation of adiponutrin expression. To better understand the in vivo regulation of adiponutrin by the insulin pathway and explain its reduced expression in type 2 diabetes, we explored (1) the association of adiponutrin with insulin sensitivity and WAT-derived proteins of known relation to insulin signaling and action and (2) the concomitant regulation of adiponutrin with the WATderived proteins by insulin infusion. The WAT-derived proteins examined were hexokinase II (HK II), the regulatory subunit p85a of phosphatidylinositol-3 kinase (PI3K), leptin, adiponectin, and acylation-stimulating protein (ASP). These proteins have been well characterized and described in relation to insulin action in healthy and in reduced insulin sensitivity state-like type 2 diabetes (Lefai et al. 2001 , Saltiel & Kahn 2001 , Faraj et al. 2004 ).
Materials and Methods

Subjects and study design
Twenty lean, healthy Caucasian young men participated in the study. Subjects underwent routine medical examination and biological testing. None had familial or personal history of diabetes, obesity, dyslipidemia, or hypertension or was on any medication. All subjects were sedentary, having !2 h-structured exercise per week, and were instructed not to engage in any exercise for the previous 48 h before the study. The study was conducted after 12 h fast. All subjects gave written consent after being informed of the nature, purpose, and possible risks of the study. The experimental protocol was approved by the ethics committee of the University of Montreal.
Analytical procedures
Hyperinsulinemic euglycemic clamp (HIEG) technique To examine the effect of hyperinsulinemia alone on adiponutrin expression in WAT in vivo, ten men underwent a 3-h HIEG clamp where hyperinsulinemia was coupled to euglycemia as previously described (DeFronzo et al. 1979) . Briefly, plasma insulin was elevated to a plateau concentration using primed-constant exogenous insulin infusion at 75 mU/m 2 per min. Plasma glucose was maintained at fasting levels using 20% dextrose infusion adjusted every 5-10 min according to repeated plasma glucose measurements. Insulin sensitivity measured by the clamp (M clamp ) represents glucose infusion rate at the last 30 min of the clamp at the steady state and is expressed as mg/kg per min (DeFronzo et al. 1979 , Karelis et al. 2005 . Insulin-stimulated data represent data analyzed at the last 30 min of the clamp.
Analysis of serum parameters Fasting serum glucose concentrations were measured with a glucose analyzer (Beckman Glucose analyzer, Mississauga, ON, Canada). Serum triglyceride (TG) and total cholesterol were measured by an automated analyzer (Beckman-Coulter, Brea, CA, USA). Serum insulin, adiponectin, and leptin levels were measured in duplicate with a commercial RIA kit (Linco Research, St Charles, MO, USA) procedure using 125 I-labeled bioactive human insulin, adiponectin, and leptin respectively as tracers and a rabbit polyclonal antibody raised against full-length peptides. Serum ASP was assayed by an in-house enzyme-linked immunosorbant assay using a monoclonal antibody as capture antibody and a polyclonal antibody as detecting antibody as described previously in detail (Maslowska et al. 1999) . Serum leptin, adiponectin, and ASP were not measured for three subjects for lack of sufficient serum samples. Insulin sensitivity in the fasting state was calculated using quantitative insulin sensitivity check index (QUICKI) as 1/(log 10 glucoseClog 10 insulin), where glucose is in mg/dl and insulin is in mU/ml (Rabasa-Lhoret et al. 2003) .
White adipose tissue biopsy S.c. abdominal WAT samples at the periumbilical level were obtained as previously described by needle biopsy under local anesthesia (Xylocaine 20 mg/ml, AstraZeneca; Vidal et al. 1996) . Basal tissue samples were collected 1 h before the initiation of the clamp. Insulin-stimulated tissue samples were collected at the end of the 3 h clamp during which insulin infusion rate was maintained at 75 mU/m 2 per min and plasma glucose concentration was maintained at fasting levels. Adipose tissues biopsies were immediately frozen in liquid nitrogen and stored at K80 8C for extraction of mRNA later.
Analysis of white adipose tissue mRNA expression levels The WAT mRNA expression levels of adiponutrin, leptin, adiponectin, complement protein C3 (ASP precursor), p85a PI3K, and HKII were measured in the basal and the insulin-stimulated states. The total RNA was extracted from frozen WAT samples using the RNeasy Total RNA Minikit (Qiagen). First-strand cDNAs were synthesized from 250 ng total RNA in the presence of 100 U Superscript II (Invitrogen) using both random hexamers and oligo (dT) primers (Promega). Real-time PCR was performed using a LightCycler (Roche Diagnostics) in a final volume of 20 ml containing 5 ml of a 100-fold dilution of the reverse transcriptase (RT) reaction and 15 ml reaction buffer from the FastStart DNA Master SYBR Green kit (Roche Diagnostics) with 3 mM MgCl 2 and the specific primers. After amplification, melting curve analysis was performed to verify the specificity of the reactions. For quantification, a standard curve was systematically generated with six different amounts (150-30 000 molecules/tube) of cDNA of the human target mRNA cloned in the pGEM plasmid (Promega). Analysis was performed using the LightCycler software (Roche Diagnostics). Gene-specific primers were designed to hybridize on different exons of the target human mRNA sequences accessible in the GenBank database.
The sequence of adiponutrin forward primer was 5 0 -GATGGAGGAGTGAGTGACAA-3 0 and the reverse primer was 5 0 -CTGAATGCATCCAAATATCC-3 0 . The sequence of leptin forward primer was 5 0 -CAC-CAG-GAT-CAA-TGA-CAT-TTC-3 0 and the reverse primer was 5 0 -TGC-CAG-TGT-CTG-GTC-CAT-CTT-G 3 0 . The sequence of adiponectin forward primer was 5 0 -AGG-CCG-TGA-TGG-CAG-AGA-TG-3 0 and the reverse primer was 5 0 -CTT-CTC-CAG-GTT-CTC-CTT-TCC-TGC-3 0 . The sequence for C3 forward primer was 5 0 -GGA-TGA-GGA-CAT-CAT-TGC-AG-3 0 and the reverse primer was 5 0 -GGC-TCT-TTC-AAG-TCC-TCA-AC-3 0 . The RT-quantitative PCR assays of these adipokines have been validated previously in human WAT for leptin mRNA (Vidal et al. 1996) , adiponectin mRNA (Tan et al. 2005) , and C3 mRNA (Dusserre et al. 2000) . For HKII and p85a PI3K mRNA, the primers used for the RT-quantitative PCR have been published (Ducluzeau et al. 2001 , Lefai et al. 2001 . The expression levels of target genes were normalized according to a reference gene hypoxanthine phosphoribosyltransferase (HPRT). The sequence of HPRT forward primer was 5 0 -TTG-CTG-ACC-TGC-TGG-ATT-AC-3 0 and the reverse primer was 5 0 -AGT-TGA-GAG-ATC-ATC-TCC-AC-3 0 .
Statistical analysis Data are expressed as meanGS.D. The correlation was analyzed by Pearson Product Moment correlation. In the correlation analysis with adiponutrin, one data point of high adiponutrin mRNA expression level was eliminated from both basal and insulin-stimulated states as they presented outliers/influential data that we believe created many false positives. The differences between subjects who did or did not undergo the HIEG clamp were examined with a two-tailed t-test, while the effect of insulin on the various measured serum and WAT parameters were analyzed by twotailed paired t-test. Statistical analysis was performed using SigmaStat (Jandel, San Rafael, CA, USA) with significance set at P%0 . 05.
Results
Basal state
Basal anthropometric and metabolic characteristics of the 20 healthy, lean young men are presented in Table 1 . As presented, adiponutrin is a relatively scarce protein as its fasting mRNA expression level was the least among the examined WAT-derived proteins, while adiponectin expression was the most abundant. At baseline, adiponutrin mRNA expression was positively correlated with the Fig. 1 ). Similar to that with adiponutrin, basal insulin or QUICKI did not correlate with leptin, adiponectin, or C3 mRNA expression levels.
Insulin-stimulated state
Out of the 20 subjects examined in the basal state, ten underwent HIEG clamps. There was no difference in all measured characteristics between the subjects who did versus those who did not do the HIEG clamp except for lower TG and ASP concentrations in the clamp subjects (clamp subjects TGZ0 . 93G0 . 19 mM versus non-clamp subjects TGZ1 . 33G0 . 43 mM and clamp subjects ASPZ16 . 34G 7 . 86 nM versus non-clamp subjects ASPZ30 . 42G5 . 98 nM, P!0 . 05 for TG and ASP).
The effect of HIEG clamp on the expression levels and the serum concentrations of the WAT-derived proteins examined in ten lean, healthy men is presented in Table 2 and Fig. 2 . Considering the range of fasting plasma insulin in healthy subjects which is 36-179 pM (Pagana & Pagana 1997) , the increase in serum insulin with the HIEG clamp was within physiological post-prandial concentrations (five to six times higher than that during fasting; English et al. 2003) . The expression levels of the gene of reference HPRT were not affected by the HIEG clamp (Table 2) . Hyperinsulinemia significantly increased serum concentrations of leptin and decreased that of adiponectin (Table 2) , while it had no effect Figure 1 Pearson correlation of WAT mRNA expression levels of p85a PI3K to those of adiponutrin (RZ0 . 54, PZ0 . 017) and HKII (RZ0 . 58, PZ0 . 010) in healthy, lean young men at baseline. 
Discussion
Recent findings by our group and others indicate that, despite being a WAT-derived protein, adiponutrin expression is not elevated in obese subjects (Liu et al. 2004 , Moldes et al. 2006 . Furthermore, fasting adiponutrin expression as well as insulin-stimulated increase in adiponutrin expression were reduced in obese type 2 diabetic subjects when compared with controls (Moldes et al. 2006) . Therefore, the regulation of adiponutrin expression in human may be altered by reduced insulin sensitivity and altered regulation of WATderived proteins in relation to insulin signaling and action in states like type 2 diabetes. In this study, we examined the association of adiponutrin with insulin sensitivity and insulinrelated WAT-derived proteins in both the basal and the insulin-stimulated states in healthy subjects to bypass the confounding effect of obesity and diabetes on the regulation of these WAT-derived proteins, including adiponutrin (Lefai et al. 2001 , Johansson et al. 2006 , Moldes et al. 2006 . The major findings of this study in healthy young men are that: (1) fasting adiponutrin expression level is correlated with that of p85a PI3K and HKII, and with serum leptin; (2) acute hyperinsulinemia simultaneously induces mRNA levels of adiponutrin, HKII, and PI3K, increases leptin concentration, and decreases adiponectin concentration; (3) insulin-stimulated adiponutrin expression is highly correlated to that of insulin-stimulated HKII, adiponectin, and leptin.
Novel findings in our study indicate that 3 h infusion of physiological doses of insulin induced an eightfold increase in adiponutrin expression, which was correlated to the percentage increase in insulin concentrations. Moreover, basal adiponutrin mRNA levels were highly correlated with those of p85a PI3K. PI3K has a pivotal role in the propagation of insulin signaling (Saltiel & Kahn 2001 ) and the regulatory subunit p85a examined in this study is the most abundant variant of the regulatory subunits of PI3K in human WAT (Lefai et al. 2001) . Many genes involved in the insulin signaling and action are under the PI3K pathway, among which HKII is examined here (Pendergrass et al. 1998) . In our study, adiponutrin expression profile mirrored that of HKII. Both adiponutrin and HKII expression levels were: (1) highly correlated to each other and to p85a PI3K in the basal state, (2) induced by insulin infusion, and (3) highly correlated in the insulin-stimulated state. Therefore, we hypothesize that, like HKII, insulin-stimulation of adiponutrin expression in human WAT may be under the PI3K pathway. Although in our study, adiponutrin expression did not correlate with that of p85a PI3K in the insulin-stimulated state, the same observation also applies to HKII, despite the previously documented regulation of HKII expression by the activity of PI3K pathway (Pendergrass et al. 1998) .
Type 2 diabetic subjects have reduced insulin action, insulin-mediated upregulation of p85a PI3K in WAT (Ducluzeau et al. 2001) , and expression of genes under the PI3K-dependent pathway like HKII (Pendergrass et al. 1998) .
Our hypothesis that insulin-mediated regulation of adiponutrin is under the PI3K-dependent pathway may therefore explain reduced adiponutrin expression in type 2 diabetes. However, it should be noted that the lack of correlation between adiponutrin expression and insulin sensitivity at fasting (QUICKI) and insulin-stimulated state (M clamp ), does not oppose our belief that the degree of insulin resistance may modulate adiponutrin expression. In the present study, the narrow ranges of insulin concentrations and sensitivity in our homogenous and healthy population may have hindered correlation analysis. However, type 2 diabetic subjects exhibit far less insulin sensitivity than our subjects which would drive reduced adiponutrin expression. Of note, the consistent correlation of adiponutrin expression to that of HKII, a major enzyme for the progress of glucose metabolism (Pendergrass et al. 1998 ) may also suggest that insulin-mediated adiponutrin expression may be glucose-dependent. In fact, this is supported by (1) our data that adiponutrin expression is only reduced in impaired insulin-sensitive and hyperglycemic (or glucose intolerant) type 2 diabetic subjects and not obese subjects (Moldes et al. 2006) and (2) in vitro findings in human adipocytes where insulin failed to induce adiponutrin expression at sub-physiological glucose concentrations (1 mM) as it did at physiological or supra-physiological concentrations of glucose (5 and 25 mM; Johansson et al. 2006) . Therefore, insulin and glucose are both important regulators of adiponutrin expression.
Another novel finding in our study is that adiponutrin expression was correlated with leptin concentration and expression at the basal and the insulin-stimulated states respectively. Leptin is a WAT-derived factor that is documented to increase insulin sensitivity by various mechanisms in central and peripheral tissues (Faraj et al. 2004) . Therefore, leptin pathway may either facilitate insulin regulation of adiponutrin or be directly involved in adiponutrin regulation. Supporting the later mechanism is the finding that adiponutrin expression is reduced in WAT of ob/ob mice, deficient for leptin gene (Lake et al. 2005) , while is increased in fa/fa rats (Baulande et al. 2001) , deficient for leptin receptor not leptin gene which is in fact increased in these rats (Guerre-Millo 1997) . Despite hyperleptinemia in type 2 diabetes, leptin resistance is suggested to be a defect in these subjects (Zimmet et al. 1999) . Accordingly, leptin resistance in type 2 diabetic would further explain our observation of a defective adiponutrin expression in these subjects (Moldes et al. 2006) . Similar to leptin, adiponectin increases the insulin sensitivity in peripheral tissue (Faraj et al. 2004) . However, adiponectin is the only known WAT-derived protein whose expression and plasma concentration are consistently reduced in both murine and human obesity (Scherer et al. 1995 , Arita et al. 1999 , Statnick et al. 2000 . Furthermore, in our study, hyperinsulinemia reduced adiponectin concentration as was documented by others (Yu et al. 2002) . Adiponectin expression and concentration are reduced in obese type 2 diabetic subjects being driven by both their obesity and their chronic hyperinsulinemia states (Statnick et al. 2000) . Therefore, high correlation of adiponutrin expression with that of adiponectin in the insulin-stimulated states would further predict reduced adiponutrin expression in obese type 2 diabetic subjects.
Adiponutrin mRNA levels in our study did not correlate with ASP concentrations or the expression of its precursor protein C3. Moreover, in contrast to adiponutrin, hyperinsulinemia did not affect ASP concentration or C3 expression in our study as was previously reported for C3 (Koistinen et al. 2001) . Although ASP concentration and C3 expression are elevated in obese type 2 diabetic subjects (Koistinen et al. 2001 , Yang et al. 2005 , this was linked to their obesity rather than their insulin resistance in one study (Koistinen et al. 2001) . Therefore, adiponutrin and ASP may be differently regulated in human. In fact, the production of ASP from human abdominal WAT increases with ingestion of a high-fat meal (Saleh et al. 1998 ) and chylomicrons are the most potent regulators of ASP production from human adipocytes (Maslowska et al. 1997 , Scantlebury et al. 1998 ). On the contrary, adiponutrin expression in mice WAT is neither stimulated with high-fat meal (Polson & Thompson 2004) nor affected by treatments of cultured human adipocytes with fatty acids (Johansson et al. 2006) . Therefore, ASP pathway and its regulators (lipid-related signals) are unlikely to contribute to the regulation of adiponutrin in human (Liu et al. 2004 ).
In conclusion, adiponutrin expression in s.c. WATof healthy, lean young men is strongly induced by acute hyperinsulinemia and is highly related to the expression levels of HKII and p85a PI3K. We hypothesize that like HKII, insulin-mediated regulation of adiponutrin expression in human WAT may be through a PI3K-dependent pathway. Accordingly, we believe that our recent finding of reduced adiponutrin expression in obese type 2 diabetic subjects may be driven by reduced insulin sensitivity, defective insulin-mediated regulation of PI3K pathway, and glucose metabolism (implying defective regulation of genes under the PI3K pathway like HKII), as well as an impaired leptin sensitivity and adiponectin expression in these subjects.
